Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial for combination of Ceftibuten/VNRX-7145.

Next Previous
X
Search
Trial Profile

A phase III trial for combination of Ceftibuten/VNRX-7145.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceftibuten/ledaborbactam etzadroxil (Primary)
  • Indications Bacterial infections; Pyelonephritis; Urinary tract infections
  • Focus Therapeutic Use
  • Sponsors VenatoRx Pharmaceuticals

    • Most Recent Events

    • 10 Oct 2023 According to a VenatoRx Pharmaceuticals media release, The contract will provide funding and technical support for the development activities required for submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing authorization of ceftibuten-ledaborbactam etzadroxil for the treatment of cUTI, including pyelonephritis. The contract will also cover a pediatric program as a post-marketing commitment.
    • 10 Oct 2023 According to a VenatoRx Pharmaceuticals media release, company announced that the Biomedical Advanced Research and Development Authority (BARDA), has awarded the company a contract to support the development of oral ceftibuten-ledaborbactam etzadroxil for the treatment of complicated urinary tract infection (cUTI), including pyelonephritis.
    • 28 Jul 2022 According to a VenatoRx Pharmaceuticals media release, the company look forward to meeting with the FDA to finalize the protocols for Phase 3 clinical trial, which is expect to initiate in the second half of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top